Trial reportPloS one2026
Symptom improvement in adenomyosis patients after ultrasound guided microwave ablation or uterine artery embolization, A randomized controlled pilot study.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04209127 (Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous/transvaginal Microwave Ablation, Evaluated by Validated Questionnaires
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of this study was to investigate alleviation of adenomyosis symptoms after microwave ablation (MWA) and uterine artery embolization (UAE) in a small pilot study. MATERIAL AND
methods20 premenopausal women with symptomatic adenomyosis were included at Danderyd Hospital, Sweden, from June 2020 to February 2023. Patients were randomized to MWA or UAE. The primary outcome was symptom severity score (SSS) at 6 months post treatment evaluated through the UFS-QoL questionnaire. The secondary outcomes were comparison of: health related quality of life (HR-QoL/UFS-QoL), Pictorial Bleeding Assessment Chart (PBAC), dysmenorrhea on a numerical rating scale (NRS), uterine volume, hemoglobin, Ca-125, prolactin and Anti Müllerian hormone (AMH), duration of hospitalization, use of pain medication and acceptability. As exploratory outcomes, we evaluated postoperative pain and return to daily activities. Clinical trials number NCT04209127.
resultsThere was no significant difference in primary outcome between the groups: SSS decreased within the MWA group from 69 to 44 (p=0.007), and within the UAE group from 88 to 47 (p=0.067). Quality of life increased significantly in the MWA group from 27 to 79 (p=0.002) and in the UAE group from 13 to 67 (p=0.013). Dysmenorrhea decreased in both groups; NRS from 6 to 1 (p=0.008) in the MWA group and from 9 to 4 (p=0.02) in the UAE group. The MWA group had significantly shorter hospitalization (0 days vs 3, p=0.004), and quicker return to daily activities (3 days vs 14, p=0.005), compared to the UAE group. No serious adverse events occurred.
conclusionIn this small pilot trial, we had low power to detect differences between groups. Both treatments resulted in a significant decrease of symptoms related to adenomyosis. Postoperative recovery seems superior after MWA, in line with previous trials. Further investigations regarding MWA for adenomyosis are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.